

Tiago Torres

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6435943/publications.pdf>

Version: 2024-02-01

64
papers

1,233
citations

430442

18
h-index

414034

32
g-index

66
all docs

66
docs citations

66
times ranked

1605
citing authors

#	ARTICLE	IF	CITATIONS
1	New Topical Therapies for Psoriasis. American Journal of Clinical Dermatology, 2022, 23, 13-24.	3.3	21
2	New Topical Therapies in Development for Atopic Dermatitis. Drugs, 2022, 82, 843-853.	4.9	21
3	Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. American Journal of Clinical Dermatology, 2021, 22, 567-579.	3.3	65
4	An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far. Drug Design, Development and Therapy, 2021, Volume 15, 1045-1053.	2.0	11
5	Targeted Therapy for Pediatric Psoriasis. Paediatric Drugs, 2021, 23, 203-212.	1.3	11
6	Serum Levels of miR-146a in Patients with Psoriasis. Molecular Diagnosis and Therapy, 2021, 25, 475-485.	1.6	7
7	Tralokinumab for the Treatment of Atopic Dermatitis. American Journal of Clinical Dermatology, 2021, 22, 625-638.	3.3	15
8	Epigenetic biomarkers as tools for chemical hazard assessment: Gene expression profiling using the model Danio rerio. Science of the Total Environment, 2021, 773, 144830.	3.9	7
9	Bimekizumab for the Treatment of Psoriasis. Drugs, 2021, 81, 1751-1762.	4.9	18
10	Authors' reply to Borg and Thoning: "Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study". American Journal of Clinical Dermatology, 2021, 22, 903-904.	3.3	1
11	A Revista da SPDV em mudança. Journal of the Portuguese Society of Dermatology and Venereology, 2021, 79, 307.	0.0	0
12	Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib. American Journal of Clinical Dermatology, 2020, 21, 783-798.	3.3	73
13	<p>>Diagnosis, Screening and Treatment of Patients with Palmoplantar Pustulosis (PPP): A Review of Current Practices and Recommendations</p>. Clinical, Cosmetic and Investigational Dermatology, 2020, Volume 13, 561-578.	0.8	28
14	JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. Drugs, 2020, 80, 341-352.	4.9	101
15	Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. American Journal of Clinical Dermatology, 2020, 21, 307-311.	3.3	60
16	Acetaminophen Removal from Water by Microalgae and Effluent Toxicity Assessment by the Zebrafish Embryo Bioassay. Water (Switzerland), 2019, 11, 1929.	1.2	22
17	Zebrafish embryo bioassays for a comprehensive evaluation of microalgae efficiency in the removal of diclofenac from water. Science of the Total Environment, 2018, 640-641, 1024-1033.	3.9	36
18	Methyl-triclosan and triclosan impact embryonic development of Danio rerio and Paracentrotus lividus. Ecotoxicology, 2017, 26, 482-489.	1.1	42

#	ARTICLE	IF	CITATIONS
19	Using early life stages of marine animals to screen the toxicity of priority hazardous and noxious substances. <i>Environmental Science and Pollution Research</i> , 2017, 24, 10510-10518.	2.7	13
20	Screening the Toxicity of Selected Personal Care Products Using Embryo Bioassays: 4-MBC, Propylparaben and Triclocarban. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1762.	1.8	48
21	Portuguese Position Paper on the Use of Biosimilars in Psoriasis. <i>Acta Medica Portuguesa</i> , 2016, 29, 574-577.	0.2	6
22	Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 349-358.	3.3	71
23	Fate, behaviour and weathering of priority HNS in the marine environment: An online tool. <i>Marine Pollution Bulletin</i> , 2016, 111, 330-338.	2.3	16
24	Statins: An undesirable class of aquatic contaminants?. <i>Aquatic Toxicology</i> , 2016, 174, 1-9.	1.9	53
25	IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 107-112.	3.3	11
26	Psoriasis strikes back! Epicardial adipose tissue: Another contributor to the higher cardiovascular risk in psoriasis. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2015, 34, 613-616.	0.2	6
27	Small Molecules in the Treatment of Psoriasis. <i>Drug Development Research</i> , 2015, 76, 215-227.	1.4	38
28	Psoriasis strikes back! Epicardial adipose tissue: Another contributor to the higher cardiovascular risk in psoriasis. <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 613-616.	0.2	10
29	Toxicity screening of Diclofenac, Propranolol, Sertraline and Simvastatin using <i>Danio rerio</i> and <i>Paracentrotus lividus</i> embryo bioassays. <i>Ecotoxicology and Environmental Safety</i> , 2015, 114, 67-74.	2.9	103
30	Effects of Tributyltin and Other Retinoid Receptor Agonists in Reproductive-Related Endpoints in the Zebrafish (<i>Danio rerio</i>). <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2015, 78, 747-760.	1.1	29
31	Ecological modelling and toxicity data coupled to assess population recovery of marine amphipod <i>Gammarus locusta</i> : Application to disturbance by chronic exposure to aniline. <i>Aquatic Toxicology</i> , 2015, 163, 60-70.	1.9	7
32	Interleucina-17 como Alvo Terapêutico na Psoríase. <i>Acta Medica Portuguesa</i> , 2014, 27, 252-258.	0.2	7
33	Biologic therapy for psoriasis - still searching for the best target. <i>Anais Brasileiros De Dermatologia</i> , 2014, 89, 365-367.	0.5	4
34	Psoriasis: The visible killer. <i>Revista Portuguesa De Cardiologia</i> , 2014, 33, 95-99.	0.2	12
35	Psoriasis: The visible killer. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2014, 33, 95-99.	0.2	6
36	Genetic Markers for Cardiovascular Disease in Psoriasis: The Missing Piece. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 93-95.	1.6	4

#	ARTICLE	IF	CITATIONS
37	Complement C3 as a marker of cardiometabolic risk in psoriasis. Archives of Dermatological Research, 2014, 306, 653-660.	1.1	12
38	Infliximab in Psoriasis and Psoriatic Arthritis. BioDrugs, 2013, 27, 13-23.	2.2	23
39	Maintenance treatment of psoriasis with cyclosporine A: Comparison between continuous and weekend therapy. Journal of the American Academy of Dermatology, 2013, 68, 341-342.	0.6	23
40	ramingham risk score underestimates cardiovascular disease risk in severe psoriatic patients: Implications in cardiovascular risk factors management and primary prevention of cardiovascular disease. Journal of Dermatology, 2013, 40, 923-926.	0.6	23
41	Treatment of palmoplantar pustulosis with ustekinumab – the importance of interfering with the IL23/Th17 pathway. European Journal of Dermatology, 2013, 23, 916-917.	0.3	4
42	Multiple myeloma in a patient under ustekinumab – are they related?. European Journal of Dermatology, 2013, 23, 567-568.	0.3	2
43	Sacroiliitis in a psoriasis patient after switching from etanercept to ustekinumab. European Journal of Dermatology, 2013, 23, 897-898.	0.3	3
44	Dusky Red Swelling of the Penis in Association with Fever and Diarrhoea: A Quiz. Acta Dermato-Venereologica, 2012, 92, 221-223.	0.6	1
45	Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues. Journal of the American Academy of Dermatology, 2012, 66, e14-e15.	0.6	54
46	The role of antinuclear autoantibodies in patients with psoriasis treated with anti-tumor necrosis factor-alpha agents: A retrospective long-term study. Journal of the American Academy of Dermatology, 2012, 66, e180-e182.	0.6	14
47	A case of erythrokeratoderma variabilis with connexin 31 gene mutation (Cx31F137L). International Journal of Dermatology, 2012, 51, 494-496.	0.5	2
48	Does treatment of metabolic syndrome components improve psoriasis? Report of three cases.. European Journal of Dermatology, 2012, 22, 270-272.	0.3	4
49	Etanercept-induced asthma in a psoriatic patient resolving with transition to ustekinumab. European Journal of Dermatology, 2012, 22, 696-697.	0.3	6
50	Residents' corner November 2011. Residents' editorial choice. European Journal of Dermatology, 2011, 21, 1029-1029.	0.3	0
51	Superficial cutaneous leiomyosarcoma of the face: Report of three cases. Journal of Dermatology, 2011, 38, 373-376.	0.6	10
52	Granuloma annulare of the penis – subcutaneous presentation. European Journal of Dermatology, 2011, 21, 448-449.	0.3	3
53	Residents' corner May 2011. European Journal of Dermatology, 2011, 21, 461-462.	0.3	0
54	Residents' corner September 2011. Residents' editorial choice. European Journal of Dermatology, 2011, 21, 826-827.	0.3	0

#	ARTICLE	IF	CITATIONS
55	Residents' corner September 2011. sQUIZ your knowledge!. European Journal of Dermatology, 2011, 21, 827-828.	0.3	0
56	Residents' corner July 2011. European Journal of Dermatology, 2011, , .	0.3	0
57	Residents' corner July 2011. European Journal of Dermatology, 2011, , .	0.3	0
58	Tender tumor of the scalp: clinicopathologic challenge. International Journal of Dermatology, 2010, 49, 605-607.	0.5	5
59	Poroceratose superficial disseminada num doente com colangiocarcinoma: manifesta�o paraneopl�sica?. Anais Brasileiros De Dermatologia, 2010, 85, 229-231.	0.5	14
60	Tratamento de hidradenite supurativa com infliximab. Anais Brasileiros De Dermatologia, 2010, 85, 576-576.	0.5	7
61	Isolated tongue lesions as the sole presentation of secondary syphilis. European Journal of Dermatology, 2010, 20, 240-241.	0.3	1
62	Widespread comedones as the sole clinical manifestation of follicular mycosis fungoides. European Journal of Dermatology, 2010, 20, 534-535.	0.3	12
63	Paecilomyces lilacinus in transplant patients: an emerging infection. European Journal of Dermatology, 2010, 20, 643-4.	0.3	5
64	Pemphigus vegetans in a patient with colonic cancer. Indian Journal of Dermatology, Venereology and Leprology, 2009, 75, 603.	0.2	12